Yong Xia1†
Hongfan Zhu1†
Shaoqing Huang2†Xinhong Guan1Xiuxiu Chen1Qian Zhang1Liu Meng1Hui Xue1Haiyan Xiang1Shenglan Lai1*Jinxing Lou1*- 1Department of Biotherapy, Shanghai University Affiliated Mengchao Cancer Hospital, Shanghai, China
- 2Department of Thoracic Surgery, Ningbo No.2 Hospital, Ningbo, China
Background: Lung cancer remains the most prevalent malignant neoplasm worldwide, with adenocarcinoma being among its most frequent subtypes. The brain is a common metastatic site in patients with lung adenocarcinoma, often associated with poor prognosis, and brain radiotherapy is the standard recommended treatment. However, the occurrence of an extracranial abscopal effect following brain-directed radiotherapy is rare due to the brain’s unique immune microenvironment.
Case description: We present the case of a 64-year-old Asian male who was admitted with complaints of “right-sided hemiplegia, reduced muscle strength, impaired ambulation, headache, projectile vomiting, and fatigue persisting for five days”. Magnetic Resonance Imaging (MRI) of the brain revealed multiple space-occupying lesions in the bilateral frontal lobes, left cerebellum, and posterior horn of the right lateral ventricle. The patient underwent palliative brain radiotherapy (targeted to the left frontal lobe and right lateral ventricle posterior horn), after which a significant extracranial abscopal effect was observed even before systemic therapy initiation, accompanied by significant improvement in neurological symptoms. Contrast-enhanced Computed Tomography (CT) of the chest demonstrated multiple space-occupying lesions in both lungs (more prominent in the lower lobe of the left lung), along with metastases involving the bilateral mediastinum, left hilar region, and bilateral supraclavicular lymph nodes. Histopathological evaluation of a biopsy obtained from the right supraclavicular lymph node, supported by morphological and immunohistochemical findings, confirmed metastatic lung adenocarcinoma with a PD-L1 tumor proportion score (TPS) ≥50%. Molecular profiling revealed a KRAS G12C mutation, while EGFR, ALK, and ROS1 alterations were absent. In accordance with NCCN guidelines, the patient received monotherapy immunotherapy with a PD-1 antibody. He achieved a sustained partial response both intracranially and extracranially for up to 24 months, with substantial improvement in quality of life.
Conclusion: This case highlights that an extracranial abscopal effect can occur following brain radiotherapy alone in lung adenocarcinoma patients with brain metastases and PD-L1 TPS ≥50%. For such patients, the combination of palliative brain radiotherapy and PD-1 antibody therapy may represent a safe and effective therapeutic strategy.
1 Introduction
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide and poses a particular challenge in patients who develop brain metastases (BMs) (1, 2). Approximately 20%–60% of individuals with advanced NSCLC will eventually develop BMs, and 7%–10% of cases present with intracranial involvement at the time of initial diagnosis. Without treatment, brain metastases are associated with a dismal prognosis, often leading to death within 1–2 months (3). In recent years, advances in radiotherapy, surgery, molecularly targeted therapies, and immune checkpoint inhibitors (ICIs) have significantly expanded treatment options for lung adenocarcinoma with brain metastases. Among these, ICIs are particularly noteworthy because they can cross the blood–brain barrier and demonstrate antitumor activity within the central nervous system. Compared with palliative chemotherapy, pembrolizumab has been shown to prolong both progression-free survival (PFS) and overall survival (OS) in NSCLC patients with or without brain metastases who express programmed cell death ligand 1 (PD-L1) with tumor proportion score (TPS) ≥1%, achieving an intracranial response rate of 20%–30% (4, 5).
For patients with NSCLC who present with symptomatic brain metastases, timely and active local treatment is essential. When the number of brain lesions is ≤3, several options are available: (1) surgical resection, (2) stereotactic radiotherapy (SRT), or (3) SRT in combination with whole-brain radiotherapy (WBRT). For patients with >3 brain metastases, WBRT or SRT may be considered as appropriate strategies.
The abscopal effect describes a unique phenomenon in which local treatment, most commonly radiotherapy, exerts systemic antitumor activity. Beyond its direct cytotoxic effect on the irradiated lesions, radiotherapy may stimulate the immune system to mount an antitumor response against distant, untreated tumor sites. The occurrence of an extracranial abscopal effect following brain-directed radiotherapy alone is exceedingly rare, likely due to the specialized immune microenvironment of the brain (6, 7).
In the present study, we describe a rare case of lung adenocarcinoma with PD-L1 TPS ≥50% in which an extracranial abscopal effect was observed following brain radiotherapy alone, accompanied by a striking and durable response to subsequent pembrolizumab therapy.
2 Case report
On May 5, 2023, a 64-year-old Chinese male presented to the Biotherapy Center of Shanghai Mengchao Cancer Hospital with complaints of “right-sided hemiplegia, decreased muscle strength, inability to ambulate, headache, projectile vomiting, and fatigue for five days”. Positron emission tomography–computed tomography (PET-CT) revealed a malignant lesion in the lower lobe of the left lung, accompanied by multiple metastatic deposits in the bilateral lungs, left hilar and mediastinal lymph nodes, bilateral supraclavicular lymph nodes, as well as numerous intracranial and osseous metastases (Supplementary Figure S1). Given the extensive tumor burden, the patient’s initial prognosis was considered poor.
Furthermore, his medical history was notable for hepatocellular carcinoma, for which he underwent radical hepatectomy in May 2012, with postoperative pathology confirming the diagnosis. To date, no evidence of recurrence has been observed. The patient reported a long-term history of tobacco use (20 cigarettes daily for approximately 30 years) and alcohol consumption (beer, three times per week, ~400 mL per occasion). He denied a history of diabetes, hypertension, autoimmune disorders, or other chronic medical conditions.
Following multidisciplinary consultation with the radiotherapy department, palliative radiotherapy was initiated to alleviate hemiplegia, targeting metastatic lesions in the left frontal lobe and the posterior horn of the right lateral ventricle (Intensity-Modulated Radiation Therapy [IMRT]: 2 Gy × 14 fractions). On May 18, 2023, a core needle biopsy of the right supraclavicular lymph node mass was performed. Histopathological evaluation confirmed metastatic lung adenocarcinoma. Immunohistochemical analysis demonstrated the following profile: CK7 (+), TTF-1 (+), Napsin A (+), P40 (–), MET (90%), CK20 (–), ALK (–), PAX-8 (–), WT-1 (–), Ki-67 (+, ~30%), and PD-L1 (TPS = 60%) (Figure 1).
Figure 1. FFPE tissue photomicrograph from lymph node metastatic lesion stained for PD-L1 (TPS=60%) assessment. L1,programmed cell death receptor-ligand 1.
Remarkably, before the initiation of systemic therapy, chest CT performed on June 5, 2023, revealed an extracranial abscopal effect, with regression of extracranial pulmonary lesions and metastatic lymph nodes exceeding 20% relative to baseline (Figure 2, Supplementary Table S1). Similarly, neurological symptoms, including right hemiplegia, headache, and projectile vomiting, showed significant improvement.
Figure 2. Extracranial abscopal effect induced brain radiotherapy. The right lateral ventricle posterior corner (red circle) and the left frontal lobe (yellow circle) metastasis are the gross tumor volume of radiotherapy.After brain radiotherapy, the left hilum of lung (A), the right mediastinal lymph node (B) and the left lung lesion (C) were significantly reduced.
The supraclavicular lymph node specimen was subsequently submitted for genetic sequencing, which identified a KRAS G12C mutation, while EGFR, ALK, and ROS1 mutations were absent. Based on the molecular and immunohistochemical findings (PD-L1 TPS = 60%), pembrolizumab monotherapy was recommended in accordance with NCCN guidelines. Treatment with pembrolizumab (200 mg every 3 weeks) commenced in June 2023 and was continued until June 2025. The patient achieved a durable partial response both intracranially and extracranially, sustained for up to 24 months (Figures 3, 4). During the course of pembrolizumab therapy, serum tumor markers carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1) demonstrated a mild decline (Supplementary Figure S2) (Supplementary Figure S3).
Figure 3. After treatment with pembrolizumab, Chest corkuted tomography [the left hilum of lung (A), the right mediastinal lymph node (B) and the left lung lesion (C)] indicated sustained partial response of the extracranial lung lesions.
Figure 4. After treatment, head magnetic resonance imaging(MRI) indicated sustained partial response of the left frontal lobe (A). right lateral ventricle posterior horn (B) and left cerebellum (C) lesions.
3 Discussion
In this report, we describe a patient with advanced primary lung adenocarcinoma harboring a KRAS G12C mutation and high PD-L1 expression (TPS ≥50%) who underwent palliative brain radiotherapy followed by PD-1 antibody therapy. The patient achieved a durable partial response (PR) lasting over 24 months, experienced an extracranial abscopal effect, and did not develop severe systemic adverse events. These findings suggest that PD-1 blockade may play a pivotal role in sustaining antitumor immunity.
The abscopal effect is generally believed to be mediated through immune system activation (8). Radiotherapy can induce immunogenic cell death, resulting in the release of tumor-associated antigens. These antigens are subsequently processed by antigen-presenting cells (APCs), which activate cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, capable of eradicating distant tumor cells (9, 10). However, the extracranial abscopal effect following brain-directed radiotherapy remains exceedingly rare. This rarity is thought to be linked to the restrictive nature of the blood–brain barrier, which both limits the release of tumor antigens into the periphery and restricts APC infiltration into the brain parenchyma (6). Studies have shown the radiation fractionation is related to the occurrence of abscopal effect. Hypofractionated Radiotherapy schedules, especially single high dose(>3 Gy), seem the most effective regimen for inducing an abscopal effect (11, 12). High PD-L1 expression in tumor cells has been shown to drive immune evasion by inducing apoptosis of activated T cells, suppressing T-cell proliferation, and inhibiting effector functions within the tumor microenvironment (13, 14). Despite these mechanisms of immune suppression, our report is the first to demonstrate that an extracranial abscopal effect can still be elicited by brain radiotherapy alone in a patient with lung adenocarcinoma and PD-L1 TPS ≥50%, even before systemic immunotherapy was initiated.
Pembrolizumab remains the standard of care for NSCLC with PD-L1 overexpression (TPS ≥50%), with reported median objective response rates, progression-free survival, and overall survival of 44.8%, 10.3 months, and 26.3 months, respectively (15). Patients with symptomatic brain metastases requiring immediate radiotherapy often show significantly reduced survival outcomes (16). In this case, radiotherapy likely initiated an endogenous antitumor immune response, characterized by increased activation of effector and memory T-cell subsets (Tcm and Tem). Subsequent administration of pembrolizumab appeared to sustain and amplify this response, enabling durable disease control and maintaining partial response for 24 months despite the presence of brain metastases.
In conclusion, this case demonstrates that even within an immunosuppressive tumor microenvironment characterized by high PD-L1 expression (TPS ≥50%), brain radiotherapy alone has the potential to induce an abscopal effect. Further prospective studies are warranted to validate and expand upon these preliminary observations.
Patient perspective
I was admitted to the hospital for treatment due to right-sided hemiplegia and inability to take care of myself in daily life. After undergoing brain radiotherapy and systemic immunotherapy, my symptoms have improved significantly, and the adverse reactions of the treatment are tolerable.
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving humans were approved by Shanghai University Affiliated Mengchao Cancer Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
YX: Conceptualization, Data curation, Writing – original draft. HZ: Investigation, Visualization, Writing – original draft. SH: Conceptualization, Formal analysis, Resources, Writing – review & editing. XG: Data curation, Formal analysis, Writing – review & editing. XC: Investigation, Methodology, Writing – review & editing. QZ: Data curation, Funding acquisition, Validation, Writing – review & editing. LM: Investigation, Project administration, Supervision, Writing – review & editing. HX: Software, Visualization, Writing – review & editing. HYX: Project administration, Supervision, Validation, Writing – review & editing. SL: Conceptualization, Methodology, Resources, Writing – original draft. JL: Conceptualization, Funding acquisition, Resources, Writing – original draft.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Acknowledgments
Thank all the staff authors for their contributions in this study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2025.1652515/full#supplementary-material.
References
1. Rybarczyk-Kasiuchnicz A, Ramlau R, and Stencel K. Treatment of brain metastases of non-small cell lung carcinoma. Int J Mol Sci. (2021) 22(2):593. doi: 10.3390/ijms22020593
2. Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. (2023) 22(1):40. doi: 10.1186/s12943-023-01740-y
3. Wang Y, Chen R, Wa Y, Ding S, Yang Y, Liao J, et al. Tumor immune microenvironment and immunotherapy in brain metastasis from non-small cell lung cancer. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.829451
4. Wang S, Hu C, Xie F, and Liu Y. Use of programmed death receptor-1 and/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer. OncoTargets Ther. (2020) 13:667–83. doi: 10.2147/OTT.S235714
5. Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. (2020) 21:655–63. doi: 10.1016/S1470-2045(20)30111-X
6. Lin X, Lu T, Xie Z, Qin Y, Liu M, Xie X, et al. Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review. Thorac Cancer. (2019) 10:1272–5. doi: 10.1111/1759-7714.13048
7. Hamilton AJ, Seid J, Verdecchia K, and Chuba P. Abscopal effect after radiosurgery for solitary brain metastasis from non-small cell lung cancer. Cureus. (2018) 10(12):e3777. doi: 10.7759/cureus.3777
8. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat OncologyBiologyPhysics. (2004) 58:862–70. doi: 10.1016/j.ijrobp.2003.09.012
9. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, and Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. OncoImmunology. (2014) 3:e28518. doi: 10.4161/onci.28518
10. Liu Y, Dong Y, Kong L, Shi F, Zhu H, and Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. (2018) 11(1):104. doi: 10.1186/s13045-018-0647-8
11. Ghaffari-Nazari H, Alimohammadi M, Alimohammadi R, Rostami E, Bakhshandeh M, Webster J T, et al. Radiation dose and schedule influence the abscopal effect in a bilateral murine CT26 tumor model. Int Immunopharmacol. (2022) 108:108737. doi: 10.1016/j.intimp.2022.108737
12. Rocchetti JR and Price J. Abscopal effect in a patient with metastatic melanoma receiving hypofractionated radiation therapy and dual immune checkpoint inhibition: A case report. Cureus. (2024) 16:e74662. doi: 10.7759/cureus.74662
13. Yi M, Zheng X, Niu M, Zhu S, Ge H, and Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. (2022) 21(1):28. doi: 10.1186/s12943-021-01489-2
14. Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.964442
15. Reck M, Rodriguez-Abreu D, Robinson GA, Hui R, Csőszi T, Fülöp A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. (2021) 39:2339–49. doi: 10.1200/JCO.21.00174
16. Frost N, Kollmeier J, Misch D, Vollbrecht C, Grah C, Matthes B, et al. Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (≥ 50%) NSCLC: real-world results with special focus on PS ≥ 2, brain metastases, and steroids. Clin Lung Cancer. (2021) 22:411–22. doi: 10.1016/j.cllc.2021.02.001
Keywords: non-small cell lung cancer, programmed cell death ligand 1, abscopal effect, radiotherapy, immunotherapy
Citation: Xia Y, Zhu H, Huang S, Guan X, Chen X, Zhang Q, Meng L, Xue H, Xiang H, Lai S and Lou J (2025) Remarkable response to pembrolizumab in PD-L1 overexpressing (≥ 50%) NSCLC and extracranial abscopal effect induced by brain radiotherapy: a case report. Front. Oncol. 15:1652515. doi: 10.3389/fonc.2025.1652515
Received: 23 June 2025; Accepted: 03 November 2025;
Published: 12 December 2025.
Edited by:
Lizza E. L. Hendriks, Maastricht University Medical Centre, NetherlandsReviewed by:
Carrie Anne Minnaar, Wits University Donald Gordon Medical Centre, South AfricaEleni Eleftheriadou, Geniko Nosokomeio Thessalonikes G Papanikolaou Pneumonologiko Tmema ESY, Greece
Copyright © 2025 Xia, Zhu, Huang, Guan, Chen, Zhang, Meng, Xue, Xiang, Lai and Lou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jinxing Lou, MTg5MTEzMzUzOTZAMTYzLmNvbQ==; Shenglan Lai, c2hlbmdsYW5sYWlAMTYzLmNvbQ==
†These authors have contributed equally to this work